for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Divi's Laboratories Ltd

DIVI.NS

Latest Trade

1,637.95INR

Change

55.55(+3.51%)

Volume

592,869

Today's Range

1,575.10

 - 

1,660.50

52 Week Range

1,212.50

 - 

1,774.95

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
1,582.40
Open
1,596.00
Volume
592,869
3M AVG Volume
11.27
Today's High
1,660.50
Today's Low
1,575.10
52 Week High
1,774.95
52 Week Low
1,212.50
Shares Out (MIL)
265.47
Market Cap (MIL)
434,824.30
Forward P/E
29.94
Dividend (Yield %)
0.98

Next Event

Divi's Laboratories Ltd Institutional Investor Meeting

Latest Developments

More

India's Divi's Labs Says Inspected By HPRA (Ireland), JAZMP (Slovenia)

India's Divi's Laboratories Says No Irregularities Found Post Income Tax Search Operation

Divi's Laboratories Says Search Enquiry By Tax Officials Continuing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Divi's Laboratories Ltd

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. The Company's geographical segments include India (Sales to customers within India) and other countries (Sales to customers outside India). Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids. It is also involved in developing alternate, non-infringing processes for APIs, for the inventors to manage late life cycle and generic drug manufacturers. The Company develops carotenoids, such as Apocarotenal, Betacarotene, Lycopene, Astaxanthin and Canthaxanthin. It manufactures tert-butoxycarbonyl (BOC), Fluorenylmethyloxycarbonyl (FMOC) and Carboxybenzyl (CBZ) protected amino acids. It manufactures ligands, such as binol and binap. The Company exports its products to European and the American countries. Its manufacturing and research and development facilities are located in the State of Andhra Pradesh and Telangana in India.

Industry

Biotechnology & Drugs

Contact Info

1-72/23(P)/Divis/303

, Divi Towers, Cyber Hills, Gachibowli,

+91.40.23786300

http://www.divislabs.com/

Executive Leadership

Murali Krishna Prasad Divi

Executive Chairman of the Board, Managing Director

L. Kishore Babu

Chief Financial Officer

P. V. Lakshmi Rajani

Compliance Officer, Company Secretary

Kiran Satchandra Divi

Whole-Time Director

Madhusudana Rao Divi

Whole-Time Director

Key Stats

2.50 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

41.0K

2018

39.1K

2019

49.5K

2020(E)

55.0K
EPS (INR)

2017

39.950

2018

33.040

2019

50.960

2020(E)

54.699
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

BRIEF-Divi's Laboratories USFDA completed evaluation of co's corrective actions in response to warning letter

* Informed that USFDA completed evaluation of co's corrective actions in response to FDA's warning letter dated April 13 Source text for Eikon: Further company coverage:

BRIEF-India's Divi's Laboratories Sept-qtr profit falls

* Sept quarter net profit 2.07 billion rupees versus profit of 2.24 billion rupees year ago

BRIEF-Divi's Laboratories gets form 483 with 6 observations at unit-2 on USFDA inspection

* Says Divi's Laboratories Limited, unit-2 has been inspected by US-FDA from September 11 to September 19, 2017

BRIEF-Divi's Laboratories says U.S. FDA will lift import alert 99-32 imposed on unit-II at Visakhapatnam

* Says informed by US-FDA that it will lift import alert 99-32 imposed on company's unit-II at Visakhapatnam

BRIEF-India's Divi's Labs March-qtr profit falls

* March quarter net profit 2.59 billion rupees versus profit3.22 billion rupees year ago

U.S. bans Indian drugmaker Divi's factory, shares hit three-year low

U.S. health regulators have banned a drug production site in India belonging to Divi's Laboratories Ltd due to manufacturing violations, sending the company's shares down to a near three-year low on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up